PURPOSE: Polymorphisms in cytokine genes can determine their level of expression and affect the phenotypic expression of immunomediated diseases, such as celiac disease (CD). We thus evaluated cytokine polymorphism prevalence in CD patients and population controls, and assessed the correlation between specific polymorphisms and celiacs' clinical characteristics. METHODS: 155 CD patients and 202 population controls were enrolled in the study. Cytokine polymorphisms (TNFalpha -308 and -238, IL-1beta -511 and +3954, IL-1b RN + 2018, IL-6 -174, IL-10 -1082, -819 and -592, TGFbeta1 + 29 and +74, IFN-gamma + 874) and HLA class II alleles were determined by sequence-specific primer polymerase chain reaction or restriction fragment length polymorphism analysis. Duodenal histology was classified using Marsh's criteria. Variables significantly associated with CD patients' characteristics were identified by multivariate logistic regression analysis. RESULTS: A significantly higher frequency of -308 TNFalpha polymorphism was observed in CD patients compared to the entire population control group, although no difference was detected when population controls were stratified according to HLA class II. Among celiacs, early onset of the disease (< or =2 year old) and the presence of a severe intestinal lesion (Marsh 3C) were significantly associated with the -1082 A/A IL-10 genotype which corresponds to a low producer phenotype (OR 3.28, 95% CI 1.49-7.19 and OR 2.60, 95% CI 1.04-6.49, respectively). CONCLUSION: The association between IL-10 genotypes and both histological severity at diagnosis and age of onset could be related to an alteration in cytokine balance, and supports the idea that the various clinical manifestations of the disease could be determined by a different genetic background.
PURPOSE: Polymorphisms in cytokine genes can determine their level of expression and affect the phenotypic expression of immunomediated diseases, such as celiac disease (CD). We thus evaluated cytokine polymorphism prevalence in CD patients and population controls, and assessed the correlation between specific polymorphisms and celiacs' clinical characteristics. METHODS: 155 CD patients and 202 population controls were enrolled in the study. Cytokine polymorphisms (TNFalpha -308 and -238, IL-1beta -511 and +3954, IL-1b RN + 2018, IL-6 -174, IL-10 -1082, -819 and -592, TGFbeta1 + 29 and +74, IFN-gamma + 874) and HLA class II alleles were determined by sequence-specific primer polymerase chain reaction or restriction fragment length polymorphism analysis. Duodenal histology was classified using Marsh's criteria. Variables significantly associated with CD patients' characteristics were identified by multivariate logistic regression analysis. RESULTS: A significantly higher frequency of -308 TNFalpha polymorphism was observed in CD patients compared to the entire population control group, although no difference was detected when population controls were stratified according to HLA class II. Among celiacs, early onset of the disease (< or =2 year old) and the presence of a severe intestinal lesion (Marsh 3C) were significantly associated with the -1082 A/A IL-10 genotype which corresponds to a low producer phenotype (OR 3.28, 95% CI 1.49-7.19 and OR 2.60, 95% CI 1.04-6.49, respectively). CONCLUSION: The association between IL-10 genotypes and both histological severity at diagnosis and age of onset could be related to an alteration in cytokine balance, and supports the idea that the various clinical manifestations of the disease could be determined by a different genetic background.
Authors: G Frisullo; V Nociti; R Iorio; A K Patanella; D Plantone; A Bianco; A Marti; G Cammarota; P A Tonali; A P Batocchi Journal: Clin Exp Immunol Date: 2009-10 Impact factor: 4.330
Authors: Saif Khan; Raju K Mandal; Arshad Jawed; Sajad A Dar; Mohd Wahid; Aditya K Panda; Mohammed Y Areeshi; Md Ekhlaque Ahmed Khan; Shafiul Haque Journal: Sci Rep Date: 2016-09-06 Impact factor: 4.379
Authors: Marta Maia Bosca-Watts; Miguel Minguez; Dolores Planelles; Samuel Navarro; Alejandro Rodriguez; Jesus Santiago; Joan Tosca; Francisco Mora Journal: World J Gastroenterol Date: 2018-01-07 Impact factor: 5.742
Authors: Vincenzo Dinallo; Irene Marafini; Davide Di Fusco; Antonio Di Grazia; Federica Laudisi; Rami Dwairi; Omero A Paoluzi; Giovanni Monteleone; Ivan Monteleone Journal: Front Immunol Date: 2019-02-04 Impact factor: 7.561
Authors: Mathilde J H Girard-Madoux; Juliane L Ober-Blöbaum; Léa M M Costes; Junda M Kel; Dicky J Lindenbergh-Kortleve; Inge Brouwers-Haspels; Astrid P Heikema; Janneke N Samsom; Björn E Clausen Journal: Oncotarget Date: 2016-05-31